AUR-AFUI-TTM1-A-1-0-R-A743-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- INFLAMMATORY_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- ANGIOGENESIS+0.450
- TNFA_SIGNALING_VIA_NFKB+0.450
- IL6_JAK_STAT3_SIGNALING+0.420
- COAGULATION+0.410
- COMPLEMENT+0.410
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.400
- MITOTIC_SPINDLE-0.380
- WNT_BETA_CATENIN_SIGNALING-0.290
- TGF_BETA_SIGNALING-0.200
- NOTCH_SIGNALING-0.190
- UV_RESPONSE_DN-0.190
- PI3K_AKT_MTOR_SIGNALING-0.090
- APICAL_JUNCTION-0.080
- ESTROGEN_RESPONSE_EARLY-0.070
- MYOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.925 |
| 2 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.907 |
| 3 | AE67DBFD-0DD0-4F86-A19F-D4789F585A2E | — | — | 0.902 |
| 4 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.901 |
| 5 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.900 |
| 6 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.897 |
| 7 | TCGA-34-5241-01A-01R-1443-07 | — | cohortSQ1 | 0.895 |
| 8 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.894 |
| 9 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.891 |
| 10 | SRR12696756 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |